Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725086 | 0.96 | SIRT6 (0.52) | SIRT6PTK2NPC1RAB9AHPGD | |
| SCHEMBL424331 | 0.85 | POLB (0.49) | SIRT6NPC1RAB9AHPGDHRH3 | |
| SCHEMBL1722269 | 0.85 | SMN1; SMN2 (0.59) | SIRT6NPC1RAB9AHPGDHRH3 | |
| SCHEMBL2916413 | 0.85 | HRH3 (0.62) | HRH3L3MBTL1L3MBTL3 | |
| SCHEMBL10330247 | 0.80 | HPGD (0.56) | PTK2NPC1RAB9AHPGDHRH3 | |
| SCHEMBL16973643 | 0.79 | PRKAA2 (0.46) | SIRT6RAB9AHRH3SMN1; SMN2MEN1 | |
| SCHEMBL24185293 | 0.78 | SIRT6 (0.44) | SIRT6HPGDALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3294698 | 0.78 | POLB (0.55) | RAB9ASMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL16973635 | 0.78 | PRKAA2 (0.44) | SIRT6L3MBTL1L3MBTL3MEN1KMT2A | |
| SCHEMBL16973768 | 0.78 | SCN7A (0.43) | SIRT6RAB9AHRH3SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642259-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | claimed |
| US-7642263-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | claimed |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | claimed |
| US-20250074922-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-03-06 | — | — | US | disclosed |
| EP-1902052-B1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2012-11-28 | — | — | EP | disclosed |
| EP-1902052-B1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2012-11-28 | — | — | EP | disclosed |
| WO-2012007758-A2 | PHARMACEUTICAL FORMULATIONS | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007758-A2 | PHARMACEUTICAL FORMULATIONS | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | WO | disclosed |
| EP-2406230-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Pfizer Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-8093252-B2 | Crystalline polymorphic form of glucokinase activator | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093252-B2 | Crystalline polymorphic form of glucokinase activator | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20080153800-A1 | NOVEL CRYSTALLINE COMPOUND | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153800-A1 | NOVEL CRYSTALLINE COMPOUND | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | SIRT6 1372/4885PTK2 1012/4885NPC1 2425/4885 |
| US-20250074922-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | SIRT6 2310/4885PTK2 4256/4885NPC1 3284/4885 |
| US-20080153800-A1 | NOVEL CRYSTALLINE COMPOUND | GCK, GCKR, GK | SIRT6 828/4885PTK2 2386/4885NPC1 1025/4885 |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | SIRT6 1459/4885PTK2 922/4885NPC1 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.